To examine the hypothesis that the inflammatory state of aging is a risk factor for accelerated renal function (RF) decline using inflammatory biomarkers and RF measures collected over 9 years of follow-up in relatively healthy individuals enrolled in the Invecchiare in Chianti study. DESIGN: Longitudinal. SETTING: Community. PARTICIPANTS: Individuals aged 60 and older with baseline estimated glomerular filtration rate (eGFR) of 60 mL/min per 1.73 m 2 and greater and no diabetes mellitus (DM) (N = 687). MEASURES: eGFR, as a proxy for RF, was determined using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at baseline and 3-, 6-, and 9-year follow-up. Incident chronic kidney disease (CKD) was defined as new-onset eGFR less than 60 mL/min per 1.73 m 2 at each follow-up. Predictors included baseline and time-dependent inflammatory biomarkers: soluble tumor necrosis factor alpha receptors (sTNFa-R1 and -R2), interleukin (IL)-6, IL-18, IL-1b, IL-1 receptor antagonist, and high-sensitivity C-reactive protein. RESULTS: Higher baseline sTNFa-R1 was significantly associated with lower eGFR over 9 years, independent of DM or blood pressure (baseline:b = À0.39, P = .001; 3-year:b = À0.26, P = .001; 6-year:b = À0.36, P = .001; 9-year:b = À0.47, P = .001). The rate of TNFa-R1 change was significantly associated with rate of eGFR change (b = À0.18, P = .001). Baseline sTNFa-R1 predicted incident CKD (per 1-standard deviation increment: 3-year: relative risk (RR) = 1.3, 95% confidence interval (CI) = 1.1-1.5; 6-year: RR = 1.5, 95% CI = 1.1-2.2; 9-year RR = 1.6, 95% CI = 1.1-2.2). Similar results were found for sTNFa-R2. CONCLUSION: Baseline TNFa-R levels and their rates of change were significantly associated with RF decline and incident CKD in older adults independent of DM or blood pressure. J Am Geriatr Soc 2018.
C hronic kidney disease (CKD) is a major health burden worldwide. 1 Diabetes mellitus (DM) and essential hypertension are established risk factors for CKD, 2 yet they do not fully explain the increased risk of decline in renal function (RF) and CKD with aging. 3, 4 The role of high concentrations of pro-inflammatory cytokines has drawn considerable attention because studies have shown that people with known CKD and high inflammation have accelerated declines in RF. 5, 6 RF also declines with aging in the absence of major comorbidities. [7] [8] [9] [10] Moreover, chronic inflammation occurs with aging. 11 There is body of evidence showing associations between inflammatory biomarkers, which activate two main inflammatory pathways, and age-related diseases such as functional decline, mobility and cognitive impairments, and mortality. [11] [12] [13] [14] Examples of such biomarkers include interleukin-6 (IL-6) and tumor necrosis factor alpha (TNFa), which activate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-jB), and IL-1b and IL-18, which are related to the nucleotide-binding oligomerization domain (NOD)-like receptor containing pyrin domain 3 (NLRP3) pathways.
The results of studies that show that inflammation predicts incident CKD are controversial because of methodological limitations, including limited numbers of inflammatory biomarkers, not considering potentially informative censoring and loss to follow-up, and limited follow-up time. [14] [15] [16] [17] [18] Moreover, most of these studies have focused on individuals with DM. In this study, we focused on IL-6 and two soluble TNFa receptors (sTNFa-R1 and sTNFa-R2) from the NF-jB pathway, IL-18 and IL-1b from the NLRP3 pathway, IL-1 receptor antagonist (IL-1RA), and high-sensitivity C-reactive protein (HS-CRP). 14 Using data from the Invecchiare in Chianti Study (InCHIANTI), 19 we tested whether baseline levels of these inflammatory biomarkers and increases in their levels over 9 years were prospectively associated with accelerated RF decline and CKD development in participants without DM who initially had normal RF.
METHODS

Study Design and Setting
Analyses were performed using 9 years of prospective data from InCHIANTI. Participants were enrolled from 1998 to 2000 and had follow-up visits every 3 years. The 3-year follow-up occurred in 2001-03, the 6-year follow-up in 2004-06, and the 9-year follow-up in 2007-09. All participants provided explicit consent that their collected data could be used for research purposes.
Participants
Of 1,453 individuals, 1,326 had measured baseline serum creatinine. Exclusion criteria for these analyses included age younger than 60 (n = 237), baseline estimated glomerular filtration rate (eGFR) less than 60 mL/min per 1.73 m 2 (n = 232), DM (defined as fasting plasma glucose ≥126 mg/dL, history of DM or antidiabetic medication) (n = 117), history of steroid use (n = 15), high-sensitivity C-reactive protein (HS-CRP) of 30 g/L or greater (n = 9) to exclude persons with severe infection or autoimmune disease that resulted in exclusion of the outliers of other biomarkers as well, and missing baseline TNFa-R1 (n = 29). Because some individuals met multiple exclusion criteria, the baseline sample size was 687.
Measurements
Inflammatory biomarkers
Serum levels of inflammatory biomarkers sTNFa-R1, sTNFa-R2, IL-18, and IL-6 were measured at baseline and all three follow-ups, and IL-1RA and IL-1b were measured only at baseline, using previously described assays. 20, 21 IL-1b and IL-1RA were measured in duplicate using highsensitivity enzyme-linked immunoabsorbent assays (ELISA) (BIOSOURCE International, Camarillo, CA). IL-18 was measured using highly sensitive quantitative sandwich assays (Quantikine HS, R&D Systems, Minneapolis, MN). sTNFa-R1 and sTNFa-R2 were measured using ELISA (BIOSOURCE International). HS-CRP was measured using colorimetric competitive immunoassay with purified protein and polyclonal anti-CRP antibodies (Calbiochem, San Diego, CA). We calculated the inter-and intra-assay coefficients of variation (CVs) at the baseline and all follow-up visits (Table S1 ). To understand within-subject variations in the inflammatory biomarkers in the total study population and in those who never developed CKD, we used a mixed-effect model for each longitudinal biomarker over 9 years of follow-up and reported random estimated within-subject variations with 95% confidence intervals (95% CIs) (Table S2) . From InCHIANTI genotyped data, we also extracted a genetic variant for R92Q mutation (rs4149584) within the TNF-R superfamily member 1A, a gene that encodes TNFa-R1, 22 because this variant increases the affinity of TNFa to TNFa-R1. 23 
Covariates
Demographic covariates included age; sex; smoking (never, former, current), marital status (not married, married, widowed), and education (number of school years). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) measured three times each in both arms, were determined as the average of the three maximum measures. Use of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and nonsteroidal antiinflammatory drugs and presence of cancer were selfreported. We adjusted for new-onset DM over 9-year follow-ups. A diagnosis of congestive heart failure (CHF) was adjudicated based on self-reported history or current treatment for CHF. Baseline urinary protein (normal range for proteinuria 0-150 mg/dL) 24 was measured (Modular P800 Analyzer, Hitachi, Roche) and normalized to urine creatinine concentration; the details of urine creatinine measure are described elsewhere. 25, 26 Creatinine levels depend on muscle mass, which often declines with age; therefore, we included calf muscle cross-sectional area (proxy for muscle mass) derived from computed tomography and changes in cross-sectional area over time. 27 Outcomes Serum creatinine was quantified using an enzymatic assay and calibrated to standardized isotope dilution mass spectrometry (IDMS). 28 Estimated glomerular filtration rate (eGFR), a proxy for RF, was estimated using IDMS-traceable serum creatinine, age, and sex using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 29, 30 We also used the rate of eGFR change over 9 years as an outcome (slope, see Statistical Analysis). We defined incident CKD as the development of eGFR less than 60 mL/min per 1.73 m 2 in individuals who had normal eGFR (≥60 mL/min per 1.73 m 2 ) at the previous visit and allowed them to re-enter to the analysis if their eGFR returned to normal in the subsequent follow-up.
Statistical analyses
Participant characteristics are reported as meansAEstandard deviations (SDs) or medians and interquartile ranges (IQRs), and percentages of total study population according to incident CKD status ( Table 1) .
The skewed inflammatory biomarkers were natural logtransformed. Then, the biomarkers, SBP, muscle cross-sectional area, and eGFR were standardized to a mean of 0 and a SD of 1 to permit comparison of their incremental predictive associations. We used inverse probability weighted generalized estimating equations (W-GEEs) to address data missing at random, after accounting for measured covariates and truncation by death. 31 We assessed the relationship between standardized baseline inflammatory biomarkers and standardized eGFR using separate W-GEE models adjusted for muscle cross-sectional area, SBP, newonset DM, and other covariates. Results are regression coefficients relating baseline biomarkers to eGFR at each follow-up. To assess which inflammatory biomarker had a stronger association with time-dependent eGFR or rate of change of eGFR over time, after evaluating collinearity (Pearson correlation, data not shown), we included all significant biomarkers in a single model, adjusting for demographic characteristics, CHF, SBP, new-onset DM, and other covariates (see Methods). Then, a parsimonious model was generated by applying backward stepwise elimination of variables with P > .10. We also examined possible threshold effects by comparing quartiles 2, 3, and 4 with quartile 1 (reference group).
We computed the rates of change in inflammatory biomarkers over time using mixed-effect models and operationalized time as a continuous variable, obtaining individual time-slopes as annual rates of change. Similarly, we modeled eGFR change using a mixed-effect model and operationalized time as a continuous variable to obtain annual rate of eGFR (slope), a common RF outcome used in longitudinal studies. We reported the mean AE SD of the slope in incident CKD and non-CKD. We determined whether baseline inflammatory biomarkers or their standardized slopes predicted the rate of eGFR change after accounting for time-varying conventional risk factors (SBP and DM) and baseline eGFR. We adjusted for baseline eGFR to account for interindividual variability.
The slopes of biomarkers and eGFR were normally distributed. We used standardized slopes (using Z-transformed slopes) for all continuous measures in the models.
The frequently used single measure of eGFR less than 60 mL/min per 1.73 m 2 was considered as an operational definition of CKD. We re-entered individuals who had eGFR less than 60 mL/min per 1.73 m 2 at one visit and eGFR of 60 mL/min per 1.73 m 2 or more at the next visit into the analyses at the next visit to calculate incidence rate for the subsequent round of analysis, treating CKD as a recurrent event. We then examined whether the inflammatory biomarkers significantly predicted incident CKD at the subsequent follow-up visits using weighted generalized linear models (Poisson distribution model, lag-time) accounting for missing values, with results expressed as relative risks (RRs) and 95% CIs. All models accounted for covariates described above. We performed all statistical analysis in Stata version 14.1 (Stata Corp., College Station, TX).
RESULTS
Participant Characteristics
Baseline characteristics of the 687 participants are summarized in Table 1 . Mean age was 72.9 (range 60-102), and 54% were women. In particular, participants who experienced incident CKD were older, more likely to be widowed, and had higher baseline levels of SBP, DBP, sTNFa-R1, sTNFa-R2, IL-6, and HS-CRP than participants who did not experience CKD (P < .05)
There were less within-subject variations in estimated inflammatory biomarkers in participants with no CKD than in those with incident CKD (Table S2) . Participants with CKD started with lower baseline eGFR than participants who did not have incident CKD (P = .001). Mean urine protein to creatinine ratio at baseline was 7.3 AE 1.9 mg/g. 
Baseline Inflammatory Biomarker and RF Over Time
In separate analyses, after adjustment for covariates, we found that higher baseline serum levels of sTNFa-R1 (b = À0.34, P < .001) and TNFa-R2 (b = À0.23, P = .001) were associated with significantly lower baseline eGFR (Figure 1) . The association between baseline levels of sTNFa-R1 and lower eGFR remained strongly significant over the 9 years of follow-up (P < .001; Figure 1) . A similar association pattern between baseline sTNFa-R2 and lower eGFR was also observed (P = .001 for all time points; Figure 1 ).
Other inflammatory biomarkers had less consistent associations with eGFR. Baseline IL-6, IL1-b, IL-1RA, and IL-18 were not associated with eGFR at baseline (P > .05) but were associated with eGFR at the 6-or 9-year follow-up visits (P < .05; Figure 1 ). We examined the possibility of a threshold effect by comparing Quartiles (Q)2, 3, and 4 with Q1 as the reference group. Q2, Q3, and Q4 of baseline sTNFa-R1 and sTNFa-R2 were all significantly associated with steeper declines in eGFR (sTNFa-R1: Q2:b = À0.12, P = .001; Q3:b = À0.20, P < .001; Q4:b = À0.21, P = .001) (sTNFa-R2: Q2:b = À0.24, P = .001; Q3: b = À0.30, P < .001; Q4:b = À0.28, P = .004). Similarly, higher baseline TNFa-R1 (b = À0.27, P = .001) and TNFa-R2 (b = À0.28, P = .001), when considered as continuous variables (dose response), were associated with steeper eGFR declines. In contrast, the association between baseline IL-6 and the slope of eGFR was not significant when considered as quartiles (Q2:b = À0.03, P = .5; Q3:b = À0.003, P = .81; Q4:b = 0.02, P = .6) or as continuous variables. Similarly, neither continuous nor quartiles of other baseline biomarkers were associated with slope of eGFR (results not shown).
In a model that included sTNFa-R1, IL-6, IL-1RA, and HS-CRP, higher baseline sTNFa-R1 levels remained Figure 1 . Effect size (standardized beta) from separate regression models examining associations between each log-transformed baseline inflammatory biomarker and longitudinal log-transformed renal function (eGFR), adjusted for covariates. sTNFa-R = soluble tumor necrosis factor alpha receptor; IL = interleukin; IL-1b = interleukin-1 beta, IL-1RA = interleukin-1 receptor antagonist; CRP = C-reactive protein.
significantly associated with lower eGFR over 9 years of follow up (3-year follow-up:b = À0.25, P = .001; 6-year follow-up:b = À0.37, P = .001; 9-year follow-up: b = À0.45, P = .001). The associations between baseline IL-6, IL-1RA, and HS-CRP and eGFR were less consistent than that between sTNFa-R1 and eGFR (Table S3 ). In a similar fashion, we replaced sTNFa-R1 with sTNFa-R2, and baseline sTNFa-R2 remained significantly associated with lower eGFR over follow-up (3-year follow-up: b = À0.11, P = .03; 6-year follow-up:b = À0.26, P = .001; 9-year follow-up:b = À0.37, P = .001). Associations with IL-6, IL-1RA, and HS-CRP also remained significant. Other inflammatory biomarkers were not included because of the backward stepwise elimination.
We estimated participant-specific time-slopes of eGFR (henceforth called rate of change; see Methods). In separate W-GEE models including each baseline biomarker, the eGFR slope was regressed on the baseline biomarkers and adjusted for baseline eGFR and other covariates. Baseline sTNFa-R1 (b = À0.10, P < .001) and IL1-RA (b = À0.05, P = .001) were significantly associated with faster declines in eGFR (Table S4) . A sensitivity analysis that removed baseline eGFR from the models resulted in even stronger estimates. In the model evaluating the association between baseline TNFa-R1 and the slope of eGFR unadjusted for baseline eGFR, the standardized beta coefficient was À0.25 (P < .001).
Rates of Inflammatory Biomarkers and RF Change (slope)
We estimated participant-specific time-slopes of inflammatory biomarkers and RF change and performed separate W-GEE models regressing standardized eGFR slope on the standardized slopes of biomarkers adjusted for baseline eGFR and other covariates. The accelerated increase in sTNFa-R1 was strongly associated with the accelerated decline in eGFR (b = À0.25, P < .001). A similar pattern was observed for the association between the rate of increase of sTNFa-R2 (b = À0.18, P < .001), IL-6 (b = À0.06, P = .01), and HS-CRP (b = À0.07, P = .002) and the rate of eGFR change in separate models (Table S5) .
After adjustment for baseline eGFR and other covariates, we simultaneously entered the slopes of the significant biomarkers in the model. sTNFa-R1 and sTNFa-R2 slopes were highly correlated (correlation coefficient = 0.98), so we excluded sTNFa-R2. The rate of change in sTNFa-R1 remained significantly associated with the rate of change in eGFR; a 1-SD increase in TNFa-R1 was associated with 0.25-SD faster decline in eGFR (b = À0.25, P < .001; Table 2 ). Having CHF and using ACEIs or ARBs were not significantly associated with the rate of change in eGFR (P = .78). When we performed similar analyses for subjects without hypertension, the baseline association and the association between rate of change in sTNFa-R1 and rate of change in eGFR remained significant (baseline:b = À0.23, P < .001; rate of change:b = À0.15, P < .001). Similarly, in these sensitivity analyses, baseline sTNFa-R2 levels (b = À0.06, P = .001) and the rate of change in sTNFa-R2 (b = À0.13 P < .001) were significantly associated with the rate of change in eGFR.
Inflammatory biomarkers and incident CKD
We assessed whether sTNFa-R1 at previous visits predicted incident CKD at 3-, 6-, and 9-year follow-up. Participants with high sTNFa-R1 levels at a given visit (baseline, 3-year, 6-year) had a significantly higher risk of incident CKD at a subsequent visit. In addition, the risk of incident CKD per 1-SD increment in baseline TNFa-R1 was increased by 30%, 50%, and 60% at 3-, 6-, and 9-year follow-ups, respectively. (3-year Relative Risk (RR) = 1.3, 95% CI = 1.1-1.5), 6-year RR = 1.5, 95% CI = 1.1-2.2, 9-year RR = 1.6, 95% CI = 1.1-2.3). Similarly, 1-SD increments of TNFa-R1 measured at the 3-and 6-year visits were significantly associated with incident CKD at later visits (Table 3) . We found similar results for TNFa-R2 and incident CKD. No other inflammatory biomarker significantly predicted incident CKD (Table S6) .
DISCUSSION
In community-dwelling older adults without DM with initially normal RF, higher baseline sTNFa-Rs are associated with accelerated eGFR decline and a greater likelihood of incident CKD. This association remained strong over 9 years of follow-up and was independent of SBP and new-onset DM. We also showed that greater increases in these inflammatory biomarkers were associated with faster decline in eGFR, independent of baseline eGFR, SBP, newonset DM, and CHF.
Our results are similar to those of other studies showing the role of TNFa-Rs in predicting incident CKD. In contrast, a study conducted in a Norwegian population showed that CRP was the inflammatory biomarker most strongly associated with incident CKD, 18 although that study was limited to a younger population (middle age) and had a shorter follow-up. In addition, data were collected from only 2 follow-up visits, which might have resulted in regression-toward-the-mean error. 18 These authors also suggested that the previously reported association between TNFa-R2 and incident CKD could be secondary to decline in renal excretion, but our findings were not consistent with this interpretation, because we evaluated the association between baseline TNFa-R levels and rate of eGFR decline independent of baseline eGFR. Moreover, our results were confirmed in lag-time models in which incident CKD was estimated independent of baseline eGFR and based only on high inflammation states in previous visits. These analytical methods should minimize interference of renal excretion of inflammatory biomarkers. Most longitudinal studies that have reported associations between TNFa-R1 or TNFa-R2 and rate of eGFR decline were performed in participants who were significantly older than the Norwegian participants. [15] [16] [17] [18] Although CRP is a marker of general inflammatory status, sTNFa-R2 is a tissue-specific biomarker usually expressed in endothelial cells and leukocytes; 32 whereas its expression in other tissues is higher in disease states. 33 Some studies have demonstrated that TNF-a or its circulating receptors are associated with poor RF, but these studies have focused mainly on individuals with DM. One such investigation demonstrated that sTNFa-Rs strongly predict Stage 3 CKD in individuals with type 1 DM without proteinuria. 34 There is also evidence that sTNFa-Rs predict end-stage renal disease in individuals with type 2 DM. 35 Furthermore, previous studies have found an association between high sTNFa-R1 levels and diabetic nephropathy. 34, 36, 37 Our results suggest that, independent of other risk factors, micro-inflammation emerges at a very early stage of RF decline and should be considered as a potential independent risk factor in older adults. [15] [16] [17] 38 Of the inflammatory biomarkers tested, sTNFa-R1 and sTNFa-R2 were the strongest and most consistent predictors of CKD. Reports indicate that TNFa induces cleavage of the TNFa-Rs from the membrane receptor. 39 TNFa-R1 activates pathways downstream to NF-jB, such as kinases of mitogen-activated protein kinase, or "death domain molecules," resulting in IL-6 synthesis or apoptosis. [40] [41] [42] sTNFa-R1 is considered an indicator of long-term activation of TNFa, 34 and it has been shown that sTNFa-R1 activates the apoptosis pathway through transforming growth factor beta-1. 43 It has been reported that the R92Q mutation (rs4149584) increases the affinity of TNF to its receptor. In our study, all individuals were normal homozygotes for this variant. 23 Consistent with previous research, we found that high HS-CRP levels were associated with the prospective, accelerated decline of RF and CKD development and that high CRP levels at 6-year follow-up predicted incident CKD at 9 years. 18 These associations were attenuated after adjustment for sTNFa-R1.
sTNFa-R1 and sTNFa-R2 predicted incident CKD. We defined CKD as a categorical threshold of eGFR of less than 60 mL/min per 1.73 m 2 , consistent with consensus definitions commonly used in large epidemiological studies. We further adjusted for baseline eGFR to minimize bias from variation in initial RF.
Although IL-6 and TNFa have been frequently reported in association with age-related outcomes, 44, 45 the mechanisms that link circulating inflammatory biomarkers and CKD risk remain hypothetical. sTNFa-Rs have been shown to play a pivotal role in the development of tubulointerstitial fibrosis and therefore nephropathy. 46 Moreover, inflammatory-induced atherosclerosis or oxidative stress detected using these biomarkers might mediate RF decline, with the latter linked to higher sTNFa-R2 levels. 45 In addition, age-related chronic inflammation might play an important role in the development of glomerulosclerosis. A study of kidney donors found that older age was associated with global glomerulosclerosis and higher odds of sclerosis in donors with hypertension. 47 Although that study did not measure inflammatory biomarkers, aging is associated with the development of inflammatory states. Another study demonstrated that angiotensin-II infusion in mice introduced a fibroinflammatory response that is followed by kidney tubulointerstitial collagen deposition mediated through the TNF-R1 signaling pathway and speculated that TNFa-R1 triggers collagen deposition. 48 A significant association between lipocalin 2 in mesangial cells and sTNFa-R2 levels and impaired kidney function has also been reported. 38 Therefore, similar persistent agerelated chronic inflammation might result in structural modification of glomerular and interstitial components of the kidneys, with resulting decline in RF.
Strengths and Limitations
Strengths of our study include the longitudinal design with multiple repeated measures of RF and inflammatory biomarkers over 9 years of follow-up and use of inverse probability weighting in the analysis to account for random missing values due to missing visits and truncation by death. Furthermore, because of uncertainty about eGFR thresholds in aging, which differentiate true disease from age-related decline, we performed multiple analyses using continuous measures of RF and an epidemiologicalbased threshold definition of CKD. These analyses demonstrate that the link between sTNFa-Rs and RF is robust and independent of baseline RF. Lack of proteinuria measures in follow-up visits is a limitation, although consensus guidelines define eGFR of less than 60 mL/min per 1.73 m 2 for longer than 3 months as Stage 3 or greater CKD, irrespective of proteinuria. In addition, albuminuria with preserved RF in older adults is primarily a manifestation of diabetic or hypertensive renal disease. Excluding individuals with these morbidities from our study, the associations between TNFa-Rs and the time-dependent slope and other RF outcomes remained significant. 26 One limitation of our study is that the follow-up intervals were 3 years apart. We operationalized time as a continuous variable to overcome this limitation for the annual slope of eGFR, but incident CKD is probably underestimated.
CONCLUSION sTNFa-Rs were the inflammatory biomarkers with the strongest association with the age-related decline in RF at baseline and over time. Temporal changes in sTNFa-Rs were associated with rate of change in RF. Moreover, these biomarkers predicted incident CKD independent of the main conventional risk factors and baseline eGFR. In contrast, in multivariate analyses, other inflammatory biomarkers, including IL-6, IL-18, and IL-1b, were not consistently significantly associated with RF outcomes. These results suggest that higher sTNFa-Rs levels, in the absence of other chronic conditions such as DM, might be an early sign of impending accelerated RF decline. Furthermore, these biomarkers could be used to identify individuals at risk of CKD who could be candidates for interventions aimed at preventing progression of RF decline.
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